[Evidence-based assessment of therapeutic agents of osteoporosis. Bisphosphonates, SERM and basic therapy in front].
D000367:Age Factors; D000368:Aged; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use; D002118:Calcium / Q000008:administration & dosage / Q000627:therapeutic use*; D002762:Cholecalciferol / Q000008:administration & dosage / Q000627:therapeutic use*; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000627:therapeutic use*; D012737:Sex Factors
D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D002762:Cholecalciferol; D020849:Raloxifene Hydrochloride; D002118:Calcium; D019386:Alendronate